Evotec shares surge 20% on Halozyme's 2 billion euro takeover bid

Halozyme Therapeutics plans to acquire Evotec for €2 billion, enhancing drug discovery capabilities. Evotec's shares surge, reflecting its potential value amid competitive differentiation and market presence.